Ensysce Biosciences, Inc. ENSC shares popped Monday following positive coverage from HC Wainwright. The firm put a price target on the stock far above current levels.
What To Know: HC Wainwright & Co analyst Raghuram Selvaraju initiated coverage on Ensysce Biosciences with a Buy rating and announced a $9 price target.
The analyst cited the innovation and optionality of the company's platforms. He further noted that Ensysce Biosciences' value proposition lies in its platforms, which include Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistant, which utilize next-generation ADFs differentiated from approved technologies and are less prone to abuse or misuse. They are intended to safeguard individuals against opioid abuse and overdoses.
In particular, TAAP-based prodrug, PF61, is used to address opioid abuse. It has shown a diminished risk of abuse through methods such as crushing, injecting, snorting, or chewing, while maintaining a comparable level of safety and effectiveness to the reference drug, OxyContin.
In terms of commercialization and partnering, the analyst proposes a target sales force of 100 to 120 specialists, with greater potential if PF614-MPAR is approved.
Total firm value was estimated at $70 million, meaning a price objective of $9 per share assuming approximately 7.5 million shares outstanding as of the end of the first quarter.
Stated risks included failure by the company to initiate Phase 2 development with PF614 and/or Phase 1 assessment of PF614-MPAR in a timely manner.
Related Link: What's Going On With PayPal Stock?
ENSC Price Action: Shares of ENSC closed Monday up 31.1% at $2.36, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
